• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Lyrica Shows Durable Effect In Fibromyalgia


WASHINGTON -- In a majority of patients with fibromyalgia, Lyrica (pregabalin) maintains its painkilling effect for several months, a researcher said here.

WASHINGTON, Nov. 16 -- In a majority of patients with fibromyalgia, Lyrica (pregabalin) maintains its painkilling effect for several months, a researcher reported here.

"This is the first study to report long-term pain relief for fibromyalgia," according to Leslie Crofford, M.D., of the University of Kentucky in Lexington, speaking at the American College of Rheumatology meeting here.

Lyrica, manufactured by Pfizer, is approved for the treatment of such conditions as diabetic neuropathy and post-herpetic neuralgia, but earlier double-blind studies have suggested that it relieves pain associated with fibromyalgia, as well as improving quality of sleep and reducing fatigue, Dr. Crofford said.

But many drugs have shown a short-term benefit in fibromyalgia, commented Eric Ruderman, M.D., of Northwestern in Chicago, who was not involved in the study. "Lots of things look interesting in fibromyalgia in small studies, short studies, but they don't really last," he said.

It was for that reason, Dr. Crofford said, that she and colleagues undertook a six-month, two-phase clinical trial involving 1,051 participants, most of them women. On average, they had a pain score of 78 on a scale of 100 and had had fibromyalgia for more than seven years.

In the first phase, lasting six weeks, all patients self-titrated to a dose of Lyrica at which they felt comfortable, to a maximum of 600 mg/day. Patients were classified as responders if they had at least a 50% reduction in pain scores at their optimum dose and reported that they were "much" or "very much" improved.

At the end of the six weeks, 663 patients (or 63%) were classified as responders and 566 entered the 26-week, double-blind, placebo-controlled part of the trial, Dr. Crofford said. Of those, 279 stayed on Lyrica, and 287 were switched to placebo.

The researchers found:

  • One in four placebo patients reported their pain worsened within seven days of beginning the double-blind part of the study, compared with 34 days for those who remained on Lyrica.
  • The time to loss of therapeutic effect was significantly longer for Lyrica patients, at P
Related Videos
© 2024 MJH Life Sciences

All rights reserved.